Zoetis (ZTS) Stock Still Looks Cheap As Earnings Expectations Stay Low

Zoetis stock has had a very weak run over the past several years, yet the current valuation checks still suggest the shares may be pricing in relatively low expectations. For investors, the contrast between the long slide in the share price and an equity screen that leans cheap is what now draws attention to Zoetis.

• Over the past 5 years, Zoetis shareholders have seen the stock decline about 60.7%, which points to a long period where sentiment has been under pressure.
• Future growth in demand for animal health products can support earnings and cash flow. At the same time, any sustained pressure on profitability or higher required returns from investors may weigh on what valuation the market is willing to pay.
• On a broad set of valuation checks, Zoetis screens as undervalued, with the company looking cheap on 5 of 6 measures according to a high value score of 5.

The issue now is whether Zoetis is a genuine value opportunity after this long drawdown or if the weaker share price is simply catching up with what the fundamentals justify.

Scan beyond Zoetis by comparing it with other stocks that also screen as potentially cheap using our 50 high quality undervalued stocks list.

Does Zoetis Look Undervalued on Earnings?

The P/E ratio is a useful way to see what investors are currently willing to pay for Zoetis earnings. It links the share price directly to the company profit base, which tends to be a key focus for established pharmaceutical businesses.

Zoetis trades on a P/E of about 12.1x, which is well below the Pharmaceuticals industry average of 16.4x and also below the peer group average of 31.4x. A tailored fair P/E ratio that accounts for Zoetis size, margins, sector and risk profile sits higher at around 21.9x. Compared with the current 12.1x, this framework suggests the market is pricing Zoetis at a sizeable discount to where it might trade if sentiment and fundamentals were more closely aligned.

This gap does not guarantee any specific outcome, but it does indicate that Zoetis stock is not being priced on an aggressive earnings multiple at the moment.

Based on the P/E comparison, Zoetis stock appears undervalued relative to both its industry and a more tailored fair multiple.

See what the numbers say about this price — find out in our valuation breakdown.

The Zoetis Narrative: What Would Justify Today's Price?

Zoetis' valuation puzzle invites a closer look at what would actually need to happen in the business for the stock to trade meaningfully above or below today's price, and that is where Simply Wall St Narratives come in on the Community page. Each Narrative spells out a specific set of assumptions about Zoetis' future growth, margins and earnings, and frames its fair value as a thesis you can revisit over time rather than a one off snapshot.

One of the top community narratives on Zoetis: 17% undervalued

"There’s hints of genuine value in the position but I figured there wouldn’t be enough people interested in their single-digit growth…"

Read one of the top narratives on Zoetis

Do you think there's more to the story for Zoetis? Head over to our Community to see what others are saying!

The Bottom Line

Zoetis currently screens as undervalued on market multiples, which suggests investors are not paying a premium for its earnings relative to peers. That discount only becomes meaningful if Zoetis can sustain earnings quality and avoid a prolonged squeeze on margins or returns on capital. For you as an investor, the key question is whether the current multiple reflects excessive caution or a fair response to business risks. The crux of the debate is whether profitability and demand in animal health hold up well enough for the market to eventually narrow that valuation gap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com